A New Oral Treatment For Type II Diabetes Mellitus
Public ClinicalTrials.gov record NCT00111800. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.
Study identification
- NCT ID
- NCT00111800
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 375 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- DEN 2.5 mg Drug
- DEN 7.5 mg Drug
- DEN 15 mg Drug
- DEN 30 mg Drug
- DEN 45 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 28, 2005 (Actual)
- Primary completion
- Jul 1, 2006 (Actual)
- Completion
- Jul 21, 2006 (Actual)
- Last update posted
- Mar 21, 2018
2005 – 2006
United States locations
- U.S. sites
- 36
- U.S. states
- 20
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Long Beach | California | 90806 | — |
| GSK Investigational Site | Pasadena | California | 91105 | — |
| GSK Investigational Site | Denver | Colorado | 80220 | — |
| GSK Investigational Site | Hollywood | Florida | 33021 | — |
| GSK Investigational Site | Miami | Florida | 33126 | — |
| GSK Investigational Site | Atlanta | Georgia | 30308 | — |
| GSK Investigational Site | Marietta | Georgia | 30066 | — |
| GSK Investigational Site | Honolulu | Hawaii | 96813 | — |
| GSK Investigational Site | Chicago | Illinois | 60607 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | — |
| GSK Investigational Site | Sunset | Louisiana | 70584 | — |
| GSK Investigational Site | Oxon Hill | Maryland | 20745 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89106 | — |
| GSK Investigational Site | Pahrump | Nevada | 89048 | — |
| GSK Investigational Site | Albany | New York | 12208 | — |
| GSK Investigational Site | Buffalo | New York | 14209 | — |
| GSK Investigational Site | Johnson City | New York | 13790 | — |
| GSK Investigational Site | Rochester | New York | 14642 | — |
| GSK Investigational Site | Syracuse | New York | 13210 | — |
| GSK Investigational Site | Durham | North Carolina | 27710 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27612 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45246 | — |
| GSK Investigational Site | Kettering | Ohio | 45429 | — |
| GSK Investigational Site | Jefferson Hills | Pennsylvania | 15025 | — |
| GSK Investigational Site | Sewickley | Pennsylvania | 15143 | — |
| GSK Investigational Site | Columbia | South Carolina | 29201 | — |
| GSK Investigational Site | Kingsport | Tennessee | 37660 | — |
| GSK Investigational Site | Arlington | Texas | 76017 | — |
| GSK Investigational Site | Dallas | Texas | 75230 | — |
| GSK Investigational Site | Dallas | Texas | 75246 | — |
| GSK Investigational Site | San Antonio | Texas | 78237 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84102 | — |
| GSK Investigational Site | Burke | Virginia | 22015 | — |
| GSK Investigational Site | Bellingham | Washington | 98226 | — |
| GSK Investigational Site | Tacoma | Washington | 98403 | — |
| GSK Investigational Site | Vancouver | Washington | 98664 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00111800, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2018 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00111800 live on ClinicalTrials.gov.